News
LFCR
5.02
-1.57%
-0.08
Lifecore Biomedical Inc <LFCR.OQ> expected to post a loss of 26 cents a share - Earnings Preview
Lifecore Biomedical Inc expected to post a loss of 26 cents a share. The company is expected to report a fall in quarterly revenue to $24.419 million from $43.36 million. Wall Street's median 12-month price target for the company is $8.00.
Reuters · 4d ago
Weekly Report: what happened at LFCR last week (0610-0614)?
Weekly Report · 5d ago
Weekly Report: what happened at LFCR last week (0603-0607)?
Weekly Report · 06/10 09:17
LIFECORE BIOMEDICAL :ON JUNE 3, GOT NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD; TRANSFER OF LISTING FROM NASDAQ
Reuters · 06/07 20:07
Weekly Report: what happened at LFCR last week (0527-0531)?
Weekly Report · 06/03 09:18
Lifecore Biomedical Inc <LFCR.OQ> expected to post a loss of 26 cents a share - Earnings Preview
Lifecore Biomedical Inc expected to post a loss of 26 cents a share. The Chaska Minnesota-based company is expected to report a fall in quarterly revenue to $ million from $ million a year ago. The one available analyst rating on the shares is "hold"
Reuters · 05/28 13:21
Weekly Report: what happened at LFCR last week (0520-0524)?
Weekly Report · 05/27 09:18
LIFECORE BIOMEDICAL INC - ON MAY 20 PAUL JOSEPHS BEGAN SERVING AS CO'S PRESIDENT AND CHIEF EXECUTIVE OFFICER
Reuters · 05/22 20:54
*22NW Fund Also Planned to Nominate Two Class I Directors, But Lifecore Said Only Class II Directors Would Be Up for Election at Aug. Meeting
Dow Jones · 05/20 20:47
*22NW Fund Nominates Nathaniel Calloway, Matthew Korenberg, Elaine Thibodeau and Beau Garrett as Class II Directors
Dow Jones · 05/20 20:45
*22NW Fund Submits Lifecore Biomedical Board Nominations
Dow Jones · 05/20 20:42
Weekly Report: what happened at LFCR last week (0513-0517)?
Weekly Report · 05/20 09:17
Lifecore Biomedical Asset Transfer for Creditor Settlement
TipRanks · 05/16 21:02
Lifecore Biomedical Completes Incremental Liquidity Initiatives
Lifecore Biomedical, Inc. Announced certain incremental liquidity measures and housekeeping matters related to divested businesses over the past week. The company is a fully integrated contract development and manufacturing organization. Lifecore is headquartered in Minneapolis, Minnesota.  
Barchart · 05/16 15:45
Weekly Report: what happened at LFCR last week (0506-0510)?
Weekly Report · 05/13 09:18
Lifecore Biomedical Changes Executive Incentives to Stock Awards
TipRanks · 05/07 21:03
Weekly Report: what happened at LFCR last week (0429-0503)?
Weekly Report · 05/06 09:19
Weekly Report: what happened at LFCR last week (0422-0426)?
Weekly Report · 04/29 09:20
Cove Street Capital Q1 2024 Letter To Shareholders
First quarter of calendar year 2024 was mostly more of the recent same for Cove Street Capital. The star of the quarter was clearly Liberty TripAdvisor Holdings. E.W. Scripps continues to be a "very, very cheap" stock. The U.S. Economy managed another positive quarter.
Seeking Alpha · 04/23 10:00
Weekly Report: what happened at LFCR last week (0415-0419)?
Weekly Report · 04/22 09:18
More
Webull provides a variety of real-time LFCR stock news. You can receive the latest news about Lifecore Biomedical Inc through multiple platforms. This information may help you make smarter investment decisions.
About LFCR
Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.